

# e-Therapeutics plc

02:20 10 Dec 2018

## Danish drugs giant Novo Nordisk to use e-Therapeutics' technology in search for new diabetes treatments

The world's largest producer of insulin is to use e-Therapeutics PLC's (LON:ETX) Network-Driven Drug Discovery (NDD) platform as it looks to discover new ways of treating type-2 diabetes.

Type-2 diabetes primarily occurs as a result of lack of exercise and obesity and is thought to account for around 90% of the 425m people with diabetes around the world.

Scientists have been tasked with finding new treatments in order to tackle the growing incidence of the condition.

**READ:** ETX and C4X team up to find new Parkinson's treatments

As part of the tie-up, Danish pharma giant Novo Nordisk will use ETX's NDD approach to identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies.

e-Therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration.

Any future license would require mutual agreement of commercial terms. Financial details of the collaboration have not been disclosed.

"We are delighted to be working with Novo Nordisk, a world leader and innovator in diabetes care," said ETX chief executive Ray Barlow.

"This collaboration highlights the use of our Network-Driven Drug Discovery (NDD) platform to understand and potentially create new treatments for complex diseases of great relevance to society, medicine and the industry."

"Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019."


Novo Nordisk's head of bioinformatics, Jan Nygaard Jensen, added: "We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

**Price:** 2.6p

**Market Cap:** £656260000M

### 1 Year Share Price Graph



August 2018    March 2019    August 2019

### Share Information

**Code:** ETX

**Listing:** AIM

**52 week High Low**  
**8.50p 1.40p**

**Sector:** Pharma & Biotech

**Website:** [www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

### Company Synopsis:

*We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology. &nbsp;*

*Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.